Valuation: Celldex Therapeutics, Inc.

Market Cap 2.77B 2.43B 2.24B 2.09B 3.93B 261B 4.01B 26.88B 10.4B 129B 10.39B 10.17B 447B P/E 2026 *
-8.13x
P/E 2027 * -8.07x
Enterprise Value 2.18B 1.91B 1.76B 1.65B 3.1B 206B 3.16B 21.21B 8.21B 102B 8.2B 8.02B 353B EV / Sales 2026 *
829x
EV / Sales 2027 * 189x
Free-Float
99.73%
Yield 2026 *
-
Yield 2027 * -
1 day+3.43%
1 week+8.73%
Current month+12.19%
1 month+11.41%
3 months+16.37%
6 months+33.56%
Current year+29.82%
1 week 32.26
Extreme 32.26
35.47
1 month 28.38
Extreme 28.38
35.47
Current year 22.33
Extreme 22.33
35.79
1 year 19.52
Extreme 19.52
35.79
3 years 14.4
Extreme 14.4
53.18
5 years 14.4
Extreme 14.4
57.2
10 years 1.5
Extreme 1.5
75.3
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 67 29/07/2014
Chief Executive Officer 64 31/08/2008
Director of Finance/CFO 55 31/03/2009
Director TitleAgeSince
Director/Board Member 64 30/11/2008
Chairman 80 04/06/2025
Director/Board Member 93 29/02/2008
Date Insider Type Main position Quantity % Market Cap.
01-01Fiscal year

Chief Financial Officer

9,634 0.0145%
12-14Fiscal year

Executive/Senior Manager

38,666 0.0582%
12-03Sell

General Counsel

4,166 0.0063%
Change 5-day change 1-year change 3-year change Capi.($)
+3.43%+8.73%+73.78%+0.92% 2.77B
-0.48%+7.20%-5.65%+3.69% 46.2B
+2.19%+11.71%+393.31%+609.31% 38.71B
+2.53%+13.93%+21.38%-10.96% 31.9B
+1.65%+3.61%+16.04%+55.24% 31.12B
-4.16%-2.58%+8.94%+26.14% 23.77B
-0.32%+12.96% - - 16.2B
+1.37%+14.53%+69.64%+136.34% 15.05B
+1.00%+10.30%+13.31%+23.36% 13.74B
+3.63%+9.53%+103.97%+106.25% 13.42B
Average +1.08%+9.10%+77.19%+105.59% 23.29B
Weighted average by Cap. +0.79%+8.71%+88.55%+136.37%

Financials

2026 *2027 *
Net sales 2.63M 2.31M 2.13M 1.99M 3.74M 249M 3.82M 25.59M 9.9M 123M 9.89M 9.68M 426M 11.96M 10.49M 9.67M 9.05M 16.97M 1.13B 17.33M 116M 44.96M 558M 44.92M 43.94M 1.93B
Net income -330M -289M -267M -250M -468M -31.14B -478M -3.21B -1.24B -15.39B -1.24B -1.21B -53.36B -370M -325M -299M -280M -526M -34.95B -537M -3.6B -1.39B -17.27B -1.39B -1.36B -59.89B
Net Debt -584M -512M -472M -442M -829M -55.1B -846M -5.67B -2.2B -27.23B -2.19B -2.15B -94.43B -507M -445M -410M -384M -720M -47.86B -735M -4.93B -1.91B -23.66B -1.91B -1.86B -82.03B
Logo Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Employees
198
Date Price Change Volume
26/06/26 US$35.26 +3.43% 4,785,830
25/06/26 US$34.09 +0.92% 1,143,621
24/06/26 US$33.78 +2.43% 1,227,357
23/06/26 US$32.98 -1.29% 669,864
22/06/26 US$33.41 +3.02% 1,957,840
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
35.26USD
Average target price
57.53USD
Spread / Average Target
+63.17%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CLDX Stock